A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Latest Information Update: 21 May 2022
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Non-small cell lung cancer; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 15 Jul 2021 This trial has been completed in Italy, according to European Clinical Trials Database
- 10 Apr 2021 According to trial design presented at the 112th Annual Meeting of the American Association for Cancer Research, an interim analysis was planned after the first 24 (mCRPC) and 20 (NSCLC) pts receiving Isa+Cemi were enrolled in Phase 2 part of this study.
- 10 Apr 2021 Trial design presented at the 112th Annual Meeting of the American Association for Cancer Research.